NPS Pharmaceuticals, Inc. (NPSP) Announces FDA Acceptance Of Biologics License Application For Natpara® For The Treatment Of Hypoparathyroidism
1/8/2014 9:17:23 AM
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review the company’s Biologics License Application (BLA) for Natpara® (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism. Under the Prescription Drug User Fee Act (PDUFA), the goal date for a decision by the FDA is October 24, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by